(Q43969504)

28 November 2017

Thalidomide treatment in myelofibrosis with myeloid metaplasia (English)

1 reference

28 November 2017

0 references

1 reference

8

Ayalew Tefferi

1 reference

28 November 2017

Michelle A Elliott

1

1 reference

28 November 2017

Ruben A Mesa

2

1 reference

28 November 2017

Chin-Yang Li

3

1 reference

28 November 2017

C Christopher Hook

4

1 reference

28 November 2017

Stephen M Ansell

5

1 reference

28 November 2017

Ralph M Levitt

6

1 reference

28 November 2017

Susan M Geyer

7

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

British Journal of Haematology

28 November 2017

1 reference

28 November 2017

117

1 reference

28 November 2017

288-296

1 reference

28 November 2017

2

1 reference

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

28 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Angiogenesis in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Idiopathic myelofibrosis: pathogenesis, natural history and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03443.X

10.1046/J.1365-2141.2002.03443.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference